BioSpace News Archive

Abata Therapeutics today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June.

Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney Disease” for its lead chronic kidney disease (CKD) program drug NP-251.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be presenting at two upcoming investor conferences.

KAHR today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors.

Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity.

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., Chief Executive Officer, will present a company presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 10:30 a.m. ET in New York, NY.

Vazyme has officially signed a global strategic cooperation agreement with Azenta Life Sciences (“Azenta”, Nasdaq: AZTA), which will promote to establish “one-stop” service process for both companies in the fields of next-generation sequencing, automated library preparation, raw material supply, experimental consumables, sample storage and more.

ByoPlanet, a wholly owned subsidiary of Plandai Biotechnology, Inc., a leading innovator in revolutionary cleaning technology, announced the completion of a third-party valuation firm’s estimates of ByoPlanet’s business and assets based on ByoPlanet’s unaudited financial statements and internal projections.

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023, at 4:40pm (PT)/7:40pm (ET).

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will present at the 2023 Jefferies Healthcare Conference.